If the tumor did not satisfy the above criteria, a biopsy was performed. When the tumor was <1 cm, ultrasonographic examination was repeated after 3 months. Statistical analyses Data are expressed as the mean �� standard deviation (SD), median (range), or n (%), as appropriate. Baseline characteristics of patients with and without LRE development were compared http://www.selleckchem.com/products/Sorafenib-Tosylate.html using the chi-squared and Fisher’s exact tests. To identify independent predictors of LRE development, univariate and subsequent multivariate Cox proportional hazard regression analyses were used. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) are indicated. Time-dependent receiver operating characteristic (ROC) curves and areas under the ROC (AUROC) were used to calculate the optimal LSM cutoff value for the prediction of LRE development, which maximized the sum of sensitivity and specificity.
The annual incidence rates of HCC were expressed in person-years. The cumulative incidence rates of HCC were calculated using the Kaplan�CMeier method. A P value<0.05 on a two-tailed test was considered statistically significant. Statistical analyses were performed using SPSS software (ver. 18.0; SPSS Inc., Chicago, IL, USA). Results Baseline characteristics The baseline characteristics of 128 patients at enrollment are summarized in Table 1. The mean age of the patients (72 men and 56 women) was 52.2 years. All patients with cirrhosis showed preserved liver function of Child�CPugh class A. The mean body mass index (BMI) and ALT were 24.0 kg/m2 and 44.4 IU/L, respectively, and the median LSM value was 12.
9 kPa. Table 1 Baseline Characteristics (n=128). F3 and F4 fibrosis stages were noted in 18 (14.1%) and 110 (85.9%) patients, respectively, and most patients (n=97, 75.8%) had a necroinflammatory activity grade of 1�C2 (Table 1). S0�C1 steatosis was identified in 127 (99.2%) patients and S2 in one (0.8%), whereas none showed S3 steatosis. LRE development and comparisons between patients with and without LREs During the follow-up period [median, 27.8 (range, 12.6�C61.6) months] constituting a total of 297 person-years, LREs developed in 19 (14.8%) patients (6.4/100 person-years; five cases with decompensation, 13 with HCC, and one with both decompensation and HCC; Table 2). The six cases of hepatic decompensation included variceal bleeding in two patients, ascites development in two, and HE in two.
SBP and HRS did not develop during the follow-up period. The cumulative incidence rates of LREs at 1, 2, and 3 years were 3.1%, 11.7%, and 16.2%, respectively (Figure 1). The incidence rate of HCC and hepatic decompensation was 4.7/100 Carfilzomib and 2.0/100 person-years, respectively. Figure 1 The cumulative incidence rates of LREs (Kaplan-Meier plot). Table 2 Comparison Between Patients with and without LRE Development.
No related posts.